Research News – Ataxia

Research News

Larimar logo

FA drug clinical trial update: Larimar Therapeutics 

Recently, Ataxia UK had a meeting with representatives from Larimar Therapeutics, a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, to discuss possible collaborations to help progress research on a potential treatment for Friedreich’s ataxia (FA). In December, Larimar announced the completion of dosing from its Phase 1 single ascending dose (SAD) …

FA drug clinical trial update: Larimar Therapeutics  Read More »

Omaveloxolone (Omav) Update

In October 2019, Reata Pharmaceuticals announced positive top-line results from their MOXIe trial testing Omaveloxolone (or Omav) in Friedreich’s ataxia (FA). In the MOXIe trial, Reata used the modified Friedreich’s Ataxia Rating Scale (mFARS) to measure the symptoms of those taking Omav vs those taking placebo (a placebo is a substance that has no therapeutic …

Omaveloxolone (Omav) Update Read More »

Donate Now
Welcome to our new site! We hope you like it.
As it's brand new, there may be a few temporary glitches such as broken links - we are working on getting these all fixed ASAP. If you'd like to give us any feedback or let us know if something isn't quite right, please email website@ataxia.org.uk
+
Scroll to Top